Change of Joint Broker

Summary by AI ^BETAClose X

Cambridge Cognition Holdings plc has announced the immediate appointment of Singer Capital Markets as Joint Corporate Broker, following the transfer of Dowgate Capital's corporate broking, advisory, and research team to Singer Capital Markets. This change in brokerage is the primary focus of the announcement and may impact how the company's shares are covered and traded.

Disclaimer*

Cambridge Cognition Holdings PLC

09 February 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Change of Joint Broker

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appointment of Singer Capital Markets as Joint Corporate Broker with immediate effect following the transfer of Dowgate Capital's corporate broking, advisory and research team to Singer Capital Markets.

For further information, please contact:

Cambridge Cognition Holdings plc

Rob Baker, Chief Executive Officer

Ronald Openshaw, Chief Financial Officer

Tel: 01223 810700

press@camcog.com

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Mark Rogers / Freddy Crossley

Rupert Dearden

Tel: 020 7886 2968

(Corporate Finance)

(Corporate Broking)

Singer Capital Markets (Joint Broker)

Amber Higgs / James Serjeant / Daniel Ingram

Tel: 020 7496 3000

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

· Clinical Studies for new pharmaceuticals;

· Academic Research for scientists to understand CNS disorders;

· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END